Detalhe da pesquisa
1.
Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077.
AIDS Behav
; 24(9): 2520-2531, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32052214
2.
Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras.
Clin Infect Dis
; 63(9): 1160-1167, 2016 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27506682
3.
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
Lancet HIV
; 10(12): e767-e778, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37952550
4.
One-on-one with Joe Eron, M.D. An update on Isentress (raltegravir) data, including some unexpected results. Interview by Jeff Berry.
Posit Aware
; 20(3): 46-7, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19492451